Merck Archives - Page 11 of 11

FDA Action Alert: Merck, Aurinia and Amgen

Amgen, Business, Calcineurin Inhibitors (CNI), Chronic Heart Failure, Clinical Trials, Collaborations, Deals, FDA, FDA, Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS), Lupus nephritis, Merck, Myelosuppression, New Drug Application (NDA), PDUFA, Priority Review, R&D, Systemic Lupus Erythematosus (SLE)

After a start-of-the-year lull, activities at the U.S. Food and Drug Administration are starting to pick up, according to BioSpace.

January 18, 2021/by Andrew Humphreys

Merck Receives Priority on Pneumococcal Vaccine, Offers Reassurance on Keytruda

Biologics License Application (BLA), Blockbusters, Checkpoint Inhibitors, European Medicines Agency (EMA), FDA, Merck, Patent Protection, Pneumococcal Disease, Pneumococcal Vaccines, Priority Review Status

The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.

January 13, 2021/by Andrew Humphreys

Merck signs U.S. supply deal for experimental Covid-19 treatment

Merck

Merck & Co. will supply about 60,000-100,000 doses of the company’s experimental Covid-19 treatment to the U.S. government for up to about $356 million.

December 23, 2020/by Andrew Humphreys

Warren Buffett Makes Big Bets on Pharma Stocks

AbbVie, Bristol Myers Squibb, Business, Coronavirus Disease (COVID-19) Pandemic, House of Representatives, Investments, Investors, Johnson & Johnson, Merck, Pfizer, Pharma, Sanofi, Teva, The Wall Street Journal

Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.

November 17, 2020/by BioSpace